| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2025 ( Subtotal = $313,355 ) |
| 2025 | 2025 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01NS124575 | Multi-scale functional connectivity in preclinical models of Parkinson's disease | 000 | 4 | NIH | 11/21/2024 | $359,442 |
| 2025 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01AG089239 | An Integrative Computational Multimodal approach to disentangle Pathophysiologic Heterogeneity of age-related White Matter Hyperintensities | 001 | 1 | NIH | 11/15/2024 | $802,017 |
| 2025 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | UH3CA247606 | Multi-parametric Perfusion MRI for Therapy Response Assessment in Brain Cancer | 000 | 3 | NIH | 10/31/2024 | $170,777 |
| 2025 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | P01AG014449 | Neurobiology of Mild Cognitive Impairment in the Elderly | 000 | 26 | NIH | 10/17/2024 | $0 |
| 2025 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | GE153343 | Community Project Funding/Congressionally Directed Spending - Non-Construction | 01 | 1 | HRSA | 10/23/2024 | $0 |
| 2025 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01AG089239 | An Integrative Computational Multimodal approach to disentangle Pathophysiologic Heterogeneity of age-related White Matter Hyperintensities | 000 | 1 | NIH | 11/13/2024 | -$802,017 |
| 2025 | 2021 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | UG3CA247606 | Multi-parametric Perfusion MRI for Therapy Response Assessment in Brain Cancer | 000 | 2 | NIH | 10/31/2024 | -$170,777 |
| 2025 | 2020 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01DA042749 | Relevance of α-Conotoxin MII Sensitive Nicotinic Receptor Subtypes to Nicotine Addiction | 000 | 4 | NIH | 10/17/2024 | -$46,087 |
|
| Issue Date FY: 2024 ( Subtotal = $26,127,675 ) (Continued on the next page) |
| 2024 | 2024 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01ES021488 | Imaging Biomarkers of Neurotoxicity in Welders | 000 | 10 | NIH | 7/2/2024 | $490,249 |
| 2024 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01AG089239 | An Integrative Computational Multimodal approach to disentangle Pathophysiologic Heterogeneity of age-related White Matter Hyperintensities | 000 | 1 | NIH | 7/30/2024 | $802,017 |
| 2024 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | UH3CA247606 | Multi-parametric Perfusion MRI for Therapy Response Assessment in Brain Cancer | 000 | 3 | NIH | 9/23/2024 | $483,637 |
| 2024 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01ES035388 | South African Manganese EnvironmentaL NeuroToxic Effects Research (SMELTER) | 001 | 1 | NIH | 9/4/2024 | -$15,628 |
| 2024 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01ES035388 | South African Manganese EnvironmentaL NeuroToxic Effects Research (SMELTER) | 000 | 1 | NIH | 8/30/2024 | $601,159 |
| 2024 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01NS138528 | Endothelial complement C3a receptor mediated cerebral injury in a murine stroke model. | 000 | 1 | NIH | 8/15/2024 | $853,135 |
| 2024 | 2024 | DIGNITY HEALTH | 350 W Thomas Rd | Phoenix | AZ | 85013-4409 | MARICOPA | USA | GE153343 | Community Project Funding/Congressionally Directed Spending - Non-Construction | 00 | 1 | HRSA | 8/1/2024 | $1,053,000 |
| 2024 | 2024 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01NS109584 | Mechanisms for intracranial aneurysm rupture | 001 | 5 | NIH | 4/23/2024 | $27,114 |
| 2024 | 2024 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01NS109584 | Mechanisms for intracranial aneurysm rupture | 000 | 5 | NIH | 11/28/2023 | $348,598 |
| 2024 | 2024 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01NS124575 | Multi-scale functional connectivity in preclinical models of Parkinson's disease | 001 | 3 | NIH | 4/23/2024 | $27,957 |
| 2024 | 2024 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01NS124575 | Multi-scale functional connectivity in preclinical models of Parkinson's disease | 000 | 3 | NIH | 11/20/2023 | $359,442 |
| 2024 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | OT2NS136939 | Access for All in ALS (ALL ALS) West Clinical Coordinating Center | 005 | 1 | NIH | 9/20/2024 | $14,234,367 |
| 2024 | 2024 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01AG077780 | Roles of aging and cellular senescence in the development of intracranial aneurysm rupture | 001 | 2 | NIH | 6/28/2024 | $60,899 |
| 2024 | 2024 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01AG077780 | Roles of aging and cellular senescence in the development of intracranial aneurysm rupture | 000 | 2 | NIH | 3/7/2024 | $548,093 |
| 2024 | 2024 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01HL156891 | Chronic Lung Allograft Dysfunction: Role for Tumor Suppressor LKB1 in Exosomes | 000 | 3 | NIH | 6/10/2024 | $414,150 |
| 2024 | 2024 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R61NS127268 | Diffusion MRI Biomarkers of Peripheral Nerve Trauma | 000 | 2 | NIH | 6/4/2024 | $797,987 |
| 2024 | 2024 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R21NS131689 | A Single Cell and Proteomic Precision Medicine Approach to Glyburide Responsive Contusion Expansion in Severe Traumatic Brain Injury | 000 | 2 | NIH | 4/2/2024 | $227,588 |
| 2024 | 2024 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | H7600510 | Ryan White Part C Outpatient EIS Program | 00 | 27 | HRSA | 3/8/2024 | $205,722 |
| 2024 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01NS120331 | Microglia contribution to disease pathogenesis in C9orf72 ALS/FTD | 002 | 4 | NIH | 8/1/2024 | $645,524 |
| 2024 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01NS120331 | Microglia contribution to disease pathogenesis in C9orf72 ALS/FTD | 002 | 4 | NIH | 8/1/2024 | $24,359 |
| 2024 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01NS120331 | Microglia contribution to disease pathogenesis in C9orf72 ALS/FTD | 002 | 4 | NIH | 8/1/2024 | $142,094 |
| 2024 | 2024 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01NS120331 | Microglia contribution to disease pathogenesis in C9orf72 ALS/FTD | 003 | 4 | NIH | 8/2/2024 | $64,322 |
| 2024 | 2024 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01NS120331 | Microglia contribution to disease pathogenesis in C9orf72 ALS/FTD | 001 | 3 | NIH | 4/10/2024 | $27,240 |
| 2024 | 2024 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01NS115815 | A Translational Evaluation of Sur1-Trpm4 Imaging Endophenotypes and Genetics to Direct Precision Medicine for Cerebral Edema After Traumatic Brain Injury | 000 | 4 | NIH | 4/25/2024 | $545,752 |
| 2024 | 2024 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | P01AG014449 | Neurobiology of Mild Cognitive Impairment in the Elderly | 000 | 26 | NIH | 6/17/2024 | $2,396,025 |
| 2024 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R21NS125535 | Investigating the role of cerebral perfusion in demyelination and repair in multiple sclerosis with MRI | 001 | 2 | NIH | 12/4/2023 | $198,494 |
| 2024 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R21NS125535 | Investigating the role of cerebral perfusion in demyelination and repair in multiple sclerosis with MRI | 000 | 2 | NIH | 11/30/2023 | -$198,494 |
| 2024 | 2023 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | OT2NS136939 | Access for All in ALS (ALL ALS) West Clinical Coordinating Center | 006 | 1 | NIH | 9/23/2024 | $0 |
| 2024 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | OT2NS136939 | Access for All in ALS (ALL ALS) West Clinical Coordinating Center | 003 | 1 | NIH | 6/12/2024 | $0 |
| 2024 | 2023 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | OT2NS136939 | Access for All in ALS (ALL ALS) West Clinical Coordinating Center | 004 | 1 | NIH | 7/24/2024 | $0 |
| 2024 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | OT2NS136939 | Access for All in ALS (ALL ALS) West Clinical Coordinating Center | 002 | 1 | NIH | 5/20/2024 | $0 |
| 2024 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | OT2NS136939 | Access for All in ALS (ALL ALS) West Clinical Coordinating Center | 001 | 1 | NIH | 3/1/2024 | $0 |
| 2024 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | OT2NS136939 | Access for All in ALS (ALL ALS) West Clinical Coordinating Center | 000 | 1 | NIH | 12/4/2023 | $0 |
| 2024 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | H7600510 | Ryan White Part C Outpatient EIS Program | 01 | 26 | HRSA | 12/15/2023 | $0 |
| 2024 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01NS120331 | Microglia contribution to disease pathogenesis in C9orf72 ALS/FTD | 000 | 3 | NIH | 1/11/2024 | $0 |
| 2024 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01NS120331 | Microglia contribution to disease pathogenesis in C9orf72 ALS/FTD | 000 | 3 | NIH | 1/11/2024 | $0 |
| 2024 | 2023 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01AG073212 | Repurposing Siponimod for Alzheimer's Disease | 000 | 3 | NIH | 8/1/2024 | $0 |
| 2024 | 2023 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01ES029524 | NOVEL PET MARKERS OF COGNITIVE IMPAIRMENT IN MANGANESENEUROTOXICITY | 004 | 5 | NIH | 4/15/2024 | $681,938 |
| 2024 | 2023 | DIGNITY HEALTH | 350 W THOMAS RD | PHOENIX | AZ | 85013-4409 | MARICOPA | USA | R01ES029524 | NOVEL PET MARKERS OF COGNITIVE IMPAIRMENT IN MANGANESENEUROTOXICITY | 004 | 5 | NIH | 4/15/2024 | $155,527 |
| 2024 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01AG059008 | MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients | 001 | 5 | NIH | 7/8/2024 | $0 |
|